EGFR and head and neck cancer: The link between toxicity and efficacy was shown in studies evaluating molecular targeted therapies, as the development of rash on monoclonal antibodies targeting the epidermal growth factor receptor resulted in better outcomes in patients with colorectal and head and neck cancer.22